Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
opioid receptor agonist
|
| gptkbp:application |
gptkb:skincare_product
|
| gptkbp:approves |
gptkb:1990
gptkb:FDA |
| gptkbp:brand |
Duragesic
Fentora Ionsys Subsys |
| gptkbp:clinical_trial |
palliative care
chronic pain severe pain cancer pain post-surgical pain |
| gptkbp:contains |
gptkb:drug
|
| gptkbp:contraindication |
severe respiratory depression
acute or post-operative pain opioid non-tolerant patients |
| gptkbp:dosage_form |
gptkb:skincare_product
100 mcg/hour 12 mcg/hour 25 mcg/hour 50 mcg/hour 75 mcg/hour |
| gptkbp:duration |
72 hours
|
| gptkbp:education |
importance of adherence
how to apply patch how to remove patch signs of overdose |
| gptkbp:formulation |
gptkb:reservoir
matrix system |
| https://www.w3.org/2000/01/rdf-schema#label |
fentanyl transdermal system
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:investment |
gptkb:drug
withdrawal symptoms overdose |
| gptkbp:is_available_on |
gptkb:spacecraft
|
| gptkbp:is_monitored_by |
required for opioid therapy
|
| gptkbp:is_used_for |
pain management
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:oversees |
fentanyl through the skin
|
| gptkbp:requires |
prescription
|
| gptkbp:side_effect |
nausea
confusion drowsiness constipation |
| gptkbp:storage |
room temperature
away from moisture |
| gptkbp:water_management |
flush unused patches down toilet
fold and dispose in trash |
| gptkbp:bfsParent |
gptkb:Fentanyl
|
| gptkbp:bfsLayer |
5
|